Read our anniversary number
After neutralizing SARS-CoV-2 in mobile culture, scientists at the University of Costa Rica conduct human testing
The progression of a lot of vaccines and treatments opposed to COVID-19 is in no way limited to the metropolitan spaces surrounding San Francisco, Boston or Washington, DC.Borrow decades of delight in the production of snake antivenomes, scientists, veterinarians and technicians The Costa Rican Clinical and Technical Institute has worked tirelessly in recent months to produce healing formulas of equine antibodies opposed to SARS-CoV-2 Drag the coronavirus guilty of COVID-19.Similar efforts are being made in Brazil and Argentina to ensure that these countries succeed in the arrival of an effective vaccine.
At the end of March, after the first case of COVID-19 in Costa Rica was diagnosed, Romon Macaya, a biochemist and public fitness expert headed by the Costa Rican Social Security Box, which manages the country’s public clinics and hospitals, filed an appeal.for a network of studies to be enrolled in combat opposed to the then nascent pandemic.”Our reaction to COVID-19 may not simply be a reaction to health care,” Macaya says.”It also had to be a clinical reaction.”
When he asked for help, he appointed the specialists in anus of the Instituto Clodomiro Picado of the University of Costa Rica, named after a famous Costa Rican scientist.”The next day we won a letter from Henning Jensen, then rector of the University of Costa Rica., saying, “We’re there. Let’s combine and paint,” Macaya recalls.
The purpose of the effort was to harness the generation and revel that the Clodomiro Picado Institute has gained in its horse antibody paints to make antvenene for snake bites for more than five decades.more than 500 people in Costa Rica and thousands more in other countries around the world.
The Chopped Clodomiro Institute has more than a hundred horses that have developed maximum immunity to snake venom after being inoculated with small amounts of toxins during an era of several weeks to several months, in addition to their use in snake, scorpion and spider anthrenes, pharmaceutical equine antibody arrangements have been used internationally to treat rabies , botulism and diphtheria.Clinical trials of the institute’s antivenomes, conducted in Colombia, Nigeria and Papua New Guinea, have shown that these antibodies are found in humans and rarely cause serious adverse effects.
More recently, the cure with equine immunoglobulin has emerged as a prospective remedy for a variety of viruses with limited remedies.These come with highly pathogenic H5N1 and H7N9 avian influenza viruses and the guilty coronavirus of Middle East Respiratory Syndrome (MERS).this has encouraged several study teams to locate tactics to produce safe and effective COVID-19 equine immunoglobulins,” says Fan Hui Wen, researcher and assignment manager at the Butantan Institute in Brazil, who also has extensive experience in making these antibodies.he did not participate in studies at the Clodomiro Picado Institute.
Costa Rica’s assignment has a familiar air.” The concept of antibody treatment for patients with COVID-19 is similar to the treatment of patients suffering from snakebite poisoning, explains Alberto Alape Girón, microbiologist and principal investigator of the COVID-19 assignment at the Clodomiro Picado Institute.”We need to generate express antibodies opposed to viral structures in horses, purify antibodies and give them to patients who are starting to fight infection but whose immune formula still does not produce enough antibodies to remove viral particles,” he adds.
The people who searched with the studios donated six horses to the institute.The animals were inoculated with changed proteins from the SARS-CoV-2 virus.Three of the horses won only S1, a part of the protein that bureaucracies the protruding peaks.that stand out from the surface of the pathogen. The other 3 animals gained a mixture of 4 coronavirus proteins, adding S1.
After 4 series of inoculations administered every two weeks, the horses produced the desired point of antibodies.At this stage, his blood was drawn and the red blood cells separated from the plasma and returned to the horses.’Plasma is a very complex aggregate comprising a lot of protein,’ explains Alape-Giron.”Antibodies are one of the most abundant proteins, but there are others.”At the pharmaceutical plant, researchers used a generation developed through the Chopped Clodomiro Institute to separate antibodies from other plasma proteins and then purified them to unload healing formulas for human testing.
In total, the plant produced 1,000 vials of 10 milliliters of purified equine antibodies, half of them had antibodies against the S1 protein and the other part contained the 4 proteins provided by the coronavirus. A 10 ml singles vial comprises approximately 80 times the amount of antibodies that can be located in 800 ml of convalescence plasma, which is the plasma given through those who triumph over SARS-CoV-2 infection,” explains Alape-Giron.
To check the effectiveness of equine antibodies, some vials were sent to George Mason University’s National Center for Biodefensive and Infectious Diseases (NCBID).’We’re looking for whether SARS-CoV-2 virus can be neutralized through antibodies.produced through the horse,’ explains Charles Bailey, biology professor and CEO of NCBID.”The control we perform on the samples is called the plate embossed neutralization control, PRNTest.We exposed antibodies produced in horses, to other dilutions, to the expanding SARS-CoV-2 virus in mobile cultivation.The virus has been neutralized. The effects of the studies are expected to be published shortly.
The next step, testing equine antibodies in patients with COVID-19, will begin with an accelerated clinical trial this month.The protection and efficacy of antibodies will be tested in an organization of 26 patients with COVID-19 who were hospitalized but not admitted to an extensive care unit.Results are expected until the end of September. If positive, studies will be moved to a large-scale trial with a large number of patients, and if equine antibodies are effective, the Clodomiro Picado Institute can immunize more horses to expand them and produce enough to fulfill Costa Rica’s call for – and that of its neighbors.He won a $500,000 grant from the Central American Bank for Economic Integration on August 13 to continue equine antibody studies.
Unlike monoclonal antibodies, which evolve to target an express molecular region, or epitope, on the surface of SARS-CoV-2 to induce an immune response, polyclonal horse antibodies opposed to SARS-CoV-2 recognize several epitopes.in a less expensive production process. Alape-Giron estimates that a vial of equine antibodies will cost $100 to produce, while a remedy with monoclonal antibodies can be 10 times more expensive.
“It’s not the most complex technology,” Macaya says.”It’s not a monoclonal antibody, but it allows us to gain speed advantages, and it’s a very pragmatic approach.”Also, “if it were a monoclonal antibody, you’d want a giant plant to produce them,” he adds.”Here horses are the factories, at least for the production part.Then comes the part of purification, which is a commercial process, however the Instituto Clodomiro Picado already has this infrastructure.
Fan says this description reflects his delight at the Butantan Institute in Brazil.”Polyclonal antibody products can be manufactured in giant quantities and with a lower load to respond to large-scale pandemic situations, such as SARS-CoV-2 infection,” he said.Says.
Currently, the Butantan Institute prepares horses to be immunized with inactivated amounts of SARS-COV-2 virus, which have been isolated, cultivated and purified, using their experience in the production of influenza vaccines, although progression protocols differ in Brazilian and Costa Rican institutes.Fan predicts that their antibodies “will have equivalent efficacy and protection in the remedy of patients with COVID-19”.
Further south of South America, Argentine scientists are also developing prospective treatment for equine antibodies from COVID-19 patients, while other researchers around the world are exploring antibodies opposed to SARS-CoV-2 of flames and cows.it’s the same: saving lives while a vaccine is expected to be available.
Costa Rica has more than 28,000 instances of COVID-19.” We have over a hundred patients in extensive care,” Macaya says.”And our ability to care extensively, as in any country, is limited.”He hopes equine antibodies will turn out to be “a very valuable tool to prevent our fitness formula from collapsing extensively and, of course, to prevent deaths.That’s the ultimate goal.”
Learn more about the Coronavirus outbreak from Scientific American here and read our magazine network canopy here.
Follow us
American Arab Scientist
You still have loose pieces left.
Support our award-winning clinical and technological advances.
Already subscribed? Connect.
Subscribers gain advantages from a more rewarded policy of clinical and technological advances.
See subscription options